Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis - Yahoo Finance

Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis  Yahoo Finance

INDIANAPOLIS, Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that baricitinib met the primary ...



Comments

Popular posts from this blog

Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC - Cancer Network